Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: TScan Therapeutics, Inc.

Market Cap 59.61M 51.48M 47.44M 44.41M 83.22M 5.67B 84.51M 560M 218M 2.76B 224M 219M 9.55B P/E Ratio 2026 *
-1.04x
P/E Ratio 2027 * -0.99x
Enterprise Value -39.26M -33.91M -31.25M -29.25M -54.81M -3.73B -55.66M -369M -144M -1.82B -147M -144M -6.29B EV / Sales 2026 *
-5.19x
EV / Sales 2027 * -1.94x
Free-Float
93.27%
Yield 2026 *
-
Yield 2027 * -
1 day-1.28%
1 week-7.11%
Current month-15.55%
1 month-21.37%
3 months-13.13%
6 months-9.69%
Current year-8.79%
1 week 0.9
Extreme 0.9012
1.03
1 month 0.9
Extreme 0.9012
1.12
Current year 0.9
Extreme 0.895
1.47
1 year 0.88
Extreme 0.8824
2.57
3 years 0.88
Extreme 0.8824
9.69
5 years 0.88
Extreme 0.8824
14.71
10 years 0.88
Extreme 0.8824
14.71
Manager TitleAgeSince
Chief Executive Officer 56 2023-03-27
Director of Finance/CFO 57 2024-01-28
Chief Tech/Sci/R&D Officer - 2024-02-05
Director TitleAgeSince
Director/Board Member 68 2021-03-22
Director/Board Member 56 2023-05-23
Chairman 55 2024-06-11
Date Insider Type Main position Quantity % Market Cap.
05-19Free

Director

67,000 0.1200%
05-19Free

Director

67,000 0.1200%
05-19
Baker Bros. Advisors LP
FreeCompany 134,000 0.2400%
Change 5-day change 1-year change 3-year change Capi.($)
-1.28%-7.11%-41.15%-65.71% 59.61M
+1.03%+2.30%+55.91%+114.22% 56.42B
+2.72%+3.26%+46.05%+44.91% 44.54B
+1.12%+2.79%-15.04%-21.68% 22.9B
+1.17%+3.85%-0.89%+403.86% 21.21B
+3.81%-5.07%+11.00%-30.62% 16.4B
+0.15%+2.24%+9.32%-39.30% 15.4B
-0.69%+0.82%+27.75%+176.72% 13.35B
+5.27%+5.54%+19.65% - 12.36B
+1.61%+1.28%+95.75%+205.26% 11.15B
Average +1.49%+1.17%+20.83%+87.52% 21.38B
Weighted average by Cap. +1.72%+2.36%+32.02%+99.55%

Financials

2026 *2027 *
Net sales 7.56M 6.53M 6.01M 5.63M 10.55M 718M 10.71M 71.02M 27.69M 350M 28.36M 27.76M 1.21B 7.81M 6.74M 6.21M 5.82M 10.9M 742M 11.07M 73.37M 28.61M 361M 29.3M 28.68M 1.25B
Net income -115M -99.39M -91.58M -85.73M -161M -10.94B -163M -1.08B -422M -5.32B -432M -423M -18.43B -125M -108M -99.34M -92.99M -174M -11.86B -177M -1.17B -457M -5.77B -468M -458M -19.99B
Net Debt -98.87M -85.39M -78.69M -73.66M -138M -9.4B -140M -929M -362M -4.57B -371M -363M -15.84B -74.76M -64.57M -59.5M -55.69M -104M -7.11B -106M -703M -274M -3.46B -281M -275M -11.98B
Logo TScan Therapeutics, Inc.
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.
Employees
139
Date Price Change Volume
26-06-12 0.9121 $ -1.28% 380,261
26-06-11 0.9239 $ +0.59% 355,035
26-06-10 0.9185 $ -4.87% 288,835
26-06-09 0.9655 $ -2.86% 326,807
26-06-08 0.9939 $ +1.22% 240,790
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.9121USD
Average target price
6.000USD
Spread / Average Target
+557.82%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRX Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!